Murdoch Childrens Research Institute (MCRI)

What Murdoch Childrens Research Institute (MCRI) does

Murdoch Children's Research Institute (MCRI), founded in 1986 and headquartered at The Royal Children's Hospital in Parkville, Melbourne, is Australia's largest child health research institute and is ranked among the top three globally for research quality and impact. The institute employs 1,800–2,000+ researchers and staff working across more than 150 common and rare childhood diseases, organised into five specialist research areas: Clinical Sciences, Genomic Medicine, Infection, Immunity and Global Health, Population Health, and Stem Cell Medicine. MCRI maintains 11,989 research partnerships and 22,876 collaborations across 124 countries and operates as a registered charity and not-for-profit research organisation.

MCRI's technology stack centres on genomic medicine, stem cell therapies, clinical research, infectious disease research, population health studies, and digital health tools. Notable proprietary and productised capabilities include the Talos open-source genomic reanalysis tool (validated in Nature Medicine with a 5.1% additional diagnostic yield across 4,735 patients), an AI epilepsy lesion detector with 94% trial accuracy, the AMR in Kids antimicrobial resistance forecasting platform (projecting resistance trends to 2035 across 82 countries), the HeadCheck concussion management app, and a speech disorder screening tool. The institute's scientific outputs span publications in major journals and direct contributions to national policy, including the establishment of Genomics Australia in 2025.

MCRI's business model is not commercial revenue in the traditional sense; the institute does not sell products or services to customers. Funding is assembled from philanthropic donations (leveraged at a 6:1 ratio to external sources), Australian government research grants (NHMRC, MRFF), international grants (notably a US$17.6M CEPI programme for COVID-19 booster research), and commercial partnerships and licensing agreements (including a US$50M deal with Retro Biosciences and an AUD$3M partnership with Anthropic). Distribution occurs through co-location with The Royal Children's Hospital, international research collaborations, national telehealth rollout, and digital platforms such as HeadCheck, with intellectual property commercialised via spin-offs including Ibnova Therapeutics.

Name

Murdoch Childrens Research Institute (MCRI)

Legal name

Murdoch Children's Research Institute

Website

https://mcri.edu.au

Company type

Private

Founded year

1986

Headcount range

1,001–5,000 employees

Short description

MCRI is Australia's largest child health research institute, employing 1,800+ researchers across 150+ childhood diseases at The Royal Children's Hospital in Melbourne. It is ranked top three globally for research quality and impact, funded through philanthropy, government grants, and licensing partnerships.

Ownership category

akta.pro rank

Product category

Pediatric Medical Research

NAICS

Medical Laboratories (621511), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Research and Development in the Physical, Engineering, and Life Sciences (54171), Medical and Diagnostic Laboratories (6215)

SIC

Services-Medical Laboratories (8071), Services-Commercial Physical & Biological Research (8731), In Vitro & In Vivo Diagnostic Substances (2835)

akta.pro primary industry

Genomics & Molecular Diagnostics (Trial Support) (HLAGAEAD)

akta.pro secondary industries

Molecular Diagnostics & Genomics Laboratories (HLAFAMAE), Genetic & Genomic Testing (germline, somatic, carrier, pharmacogenomics) (HLAAALAD), Pediatric Infectious Disease (HLAKAGAE), Molecular & Genetic Testing (PCR/NGS/qPCR) (HLAGADAF)

Keywords

• Pediatric medical research
• Child health research
• Genomic medicine
• Clinical trials
• Stem cell medicine

Headquarters

HQ city

Melbourne

HQ country

Australia

HQ region

Oceania

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Infrastructure, Operations, Marketing or Sales

Revenue model

1. Philanthropic Donations: Donations from individuals, families, and supporters help accelerate breakthroughs. MCRI is a registered charity. For every dollar donated, MCRI leverages a further $6 from external sources.
2. Government Research Grants: Funding from National Health and Medical Research Council (NHMRC), Medical Research Future Fund (MRFF), and other government bodies supporting research programs and centres of research excellence.
3. Licensing and Commercialisation: Commercial partnerships and licensing agreements including $50 million licensing partnership with Retro Biosciences to advance bone marrow stem cell technology.
4. CEPI Funding: International funding from CEPI (Coalition for Epidemic Preparedness Innovations) for vaccine research programs, with $17.6 million program for COVID-19 booster strategies.

Go-to-market motion1 record

Distribution channels5 records

Marketing channels8 records

Core offering

MCRI is Australia's largest child health research institute conducting research across genomic medicine, stem cell medicine, clinical sciences, infection and immunity, and population health for over 150 childhood diseases. The institute translates laboratory discoveries into practical treatments, diagnostic tools, vaccines, and digital health applications, leveraging co-location with The Royal Children's Hospital to move research rapidly from bench to bedside.

Differentiator

Problem solved

Functional benefit

Products and services

• AMR in Kids Platform Web-based forecasting platform providing region and pathogen-specific antimicrobial resistance projections to 2035. Developed for clinicians, researchers, and policymakers globally, the platform helps identify emerging resistance threats and guide antibiotic stewardship decisions for pediatric populations.
• Speech Disorder Screening Tool Screening tool designed to identify children at genuine risk of persistent speech disorders, distinguishing typical developmental speech errors from conditions requiring clinical intervention. The tool aims to address over-diagnosis concerns and improve allocation of limited speech pathology resources for pediatric healthcare providers.
• HeadCheck (Concussion Essentials) App Evidence-based smartphone application providing concussion management including sideline assessment tools and tailored guidance for return to activities. Developed in collaboration with AFL and Curve Tomorrow for parents, coaches, and healthcare providers.
• Talos Genomic Reanalysis Tool Open-source genomic tool that automatically reanalyses stored DNA data to detect rare diseases. Validated at a cost of less than USD$12 per 1,000 genomes, achieving 5.1% additional diagnostic yield with 241 new diagnoses in 4,735 previously undiagnosed patients across US and Australian cohorts.
• Victorian Clinical Genetics Services (VCGS) Not-for-profit clinical and laboratory pathology genetic services provided by a wholly-owned subsidiary of MCRI. VCGS delivers human-centred genetic healthcare, research and policy support to thousands of Australian families every year.
• Generation Victoria (GenV) Population health research platform operated by MCRI as a wholly-owned subsidiary. GenV is described as the world's largest study of children and parents, capturing a complete picture of health and wellbeing of a whole generation to unlock discoveries that improve the lives of all families.
• Bone Marrow Stem Cell Technology Platform Patient-specific bone marrow stem cell production platform developed by MCRI researchers and licensed to Retro Biosciences in a $50 million partnership to advance the technology toward clinical applications.
• RV3-BB Rotavirus Vaccine Rotavirus vaccine candidate developed by MCRI researchers including Professor Ruth Bishop. The vaccine addresses the cause of severe diarrhoea identified in 1973 and has been trialed in low-income countries where it could save millions of babies worldwide.

Quantifiable outcome

• 94% of child concussion patients showed symptom improvement within eight weeks under new treatment protocols
• +4 more outcomes

Named customers3 records

Segments3 records

Ideal customer profiles5 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability8 records

Feature6 records

Partnerships

23 partnerships are on record, tiered strategic, core, flagship and minor.

• AnthropicstrategicStrategic or Co-development Partner · 31 March 2026AI company Anthropic signed MOU with Australian government providing Claude AI technology and data services. Partnership includes $3 million for Australian research institutions including MCRI for disease diagnosis, genetic research, and workforce AI training.
• The Royal Children's HospitalcoreStrategic or Co-development PartnerCo-location and integration enables researchers and clinicians to work side by side, allowing discoveries to move rapidly from laboratory to patient care. Many MCRI researchers are clinicians at the hospital.
• University of Melbourne (Department of Paediatrics)coreStrategic or Co-development PartnerPart of Melbourne Children's Campus partnership, creating better health outcomes for children through interdisciplinary research teams combining expertise from all three organisations.
• Victorian Clinical Genetics Services (VCGS)coreStrategic or Co-development PartnerVCGS provides not-for-profit clinical and laboratory pathology genetic services to thousands of Australian families every year, driving human-centred genetic healthcare, research and policy.
• Generation Victoria (GenV)flagshipStrategic or Co-development PartnerWorld's largest study of children and parents, capturing complete picture of health and wellbeing of a whole generation to unlock discoveries that improve lives of all families.
• Centre for Population Genomics (CPG)strategicTechnology or IntegrationWorking to create a world in which genomic information enables comprehensive disease prediction, accurate diagnosis and effective therapeutics for all people.
• University of SydneystrategicStrategic or Co-development PartnerCollaborated on global study of antimicrobial resistance in children analyzing over 106,000 infection samples from 82 countries, published in JAMA Pediatrics.
• Clinton Health Access InitiativestrategicStrategic or Co-development PartnerCollaborated on global antimicrobial resistance study providing expertise on healthcare resource availability in countries with fewer resources.
• The Chinese University of Hong KongstrategicStrategic or Co-development PartnerInternational collaboration on antimicrobial resistance research spanning 82 countries and published in JAMA Pediatrics.
• QIMR BerghoferstrategicStrategic or Co-development PartnerLaunched Ibnova Therapeutics through Australian-Danish research partnership to accelerate stem cell-based treatments for heart disease, with plans for human clinical trials within three to five years.
• Broad InstitutestrategicStrategic or Co-development PartnerCollaborated on Talos genomic tool development and validation across US and Australian cohorts for rare disease detection.
• Microsoft ResearchstrategicTechnology or IntegrationPartnered with MCRI, VCGS, and Broad Institute on Talos genomic reanalysis tool development for automated rare disease detection.
• Australian National University (ANU)strategicStrategic or Co-development PartnerOne of four Australian research institutions receiving $3 million in Anthropic API credits for AI research projects.
• Garvan Institute of Medical ResearchstrategicStrategic or Co-development PartnerOne of four Australian research institutions receiving Anthropic partnership funding for disease diagnosis and genetic research.
• Curtin UniversitystrategicStrategic or Co-development PartnerOne of four Australian research institutions in Anthropic partnership for AI research in healthcare.
• reNEW - Novo Nordisk Foundation Center for Stem Cell MedicineflagshipStrategic or Co-development PartnerInternational collaboration that paves the way for future stem cell-based treatments, stimulates global investment in stem cell medicine and creates highly skilled jobs.
• WHO Collaborating CentresstrategicStrategic or Co-development PartnerMCRI designated as WHO Collaborating Centre supporting organisation's programmes in child health.
• Melbourne Children's Trials Centre (MCTC)strategicStrategic or Co-development PartnerState-of-the-art centre supporting clinicians and researchers in initiating and performing trials of new therapies.
• IPCHiP - International Precision Child Health PartnershipstrategicStrategic or Co-development PartnerInternational partnership advancing precision child health through global collaboration.
• Big WminorGTM or Marketing PartnerCorporate partner that raised over $1.3 million through fundraising initiatives for heart research over seven years.
• News Corp AustraliaminorGTM or Marketing PartnerFounding media partner for MCRI Step-a-thon initiative encouraging children to step to a healthier future.
• Ibnova TherapeuticsstrategicStrategic or Co-development PartnerSpin-off biotech company launched through Australian-Danish research partnership to advance stem cell-based treatments for heart disease with human trials planned within 3-5 years.
• Melbourne Children's CampuscoreStrategic or Co-development PartnerPartnership between MCRI, The Royal Children's Hospital, and University of Melbourne creating interdisciplinary research teams solving problems in integrated way for faster translational outcomes.

Scale indicators13 records

Recent moves8 records

Expansion highlights7 records

Direct peers

• Children's Medical Research Institute (CMRI): Westmead-based Australian independent pediatric research institute focused on genetics, cancer, and stem cell research. Comparable NFP peer with overlapping genomic and cell biology programs.
• Great Ormond Street Hospital (GOSH) and UCL Great Ormond Street Institute of Child Health: UK's premier pediatric research hospital paired with a dedicated child health research institute. Comparable to MCRI in combining clinical pediatric services with high-output translational research.
• Cincinnati Children's Hospital Medical Center: Top-ranked US pediatric medical center with major basic and translational research programs. Highly comparable to MCRI in its integration of clinical care, genomics, and academic research output.
• Boston Children's Hospital: Harvard-affiliated pediatric research hospital and the largest pediatric research enterprise in the US. Directly comparable as a globally leading pediatric research institution with co-located clinical and research functions similar to MCRI's Royal Children's Hospital model.
• Telethon Kids Institute: Perth-based Australian pediatric research institute focused on child health. Closest geographic peer to MCRI within Australia, with overlapping disease areas and similar NFP research-institute structure.
• The Hospital for Sick Children (SickKids) Research Institute: Canada's leading pediatric research hospital, affiliated with the University of Toronto, with large-scale genomic and translational pediatric research. Comparable peer in scope of pediatric disease focus and academic-medical integration.
• Children's Hospital of Philadelphia (CHOP) Research Institute: CHOP houses one of the largest pediatric research institutes in the US with integrated clinical-research operations. Comparable to MCRI in scale of pediatric genomic, stem cell, and clinical trial activity.
• Seattle Children's Research Institute: Major US pediatric research institute with strengths in genomics, immunotherapy, and infectious disease. Comparable as a standalone pediatric research institute embedded within a children's hospital.

Broad incumbents

• Garvan Institute of Medical Research: Sydney-based Australian medical research institute with strong genomics and translational programs, including recent AI initiatives. Comparable as an Australian peer in genomic medicine research; broader than pediatrics but operationally similar in scale and NFP model.
• Walter and Eliza Hall Institute of Medical Research (WEHI): Australia's oldest medical research institute, with strengths in immunology, genomics, and cell biology. Comparable as a leading Australian NFP medical research organization, though broader in scope beyond pediatrics.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat7 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/MCRI_for_kids
• Facebookfacebook.com/MurdochChildrensResearchInstitute
• LinkedInlinkedin.com/company/murdoch-childrens-research-institute

Revenue estimate

Valuation estimate

Number of profiles

Profiles16 records

Subsidiaries2 records

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Murdoch Childrens Research Institute (MCRI)